Biotech Values

[microcapfun]

>>GSK Acquires SIRT at 85% Premium to Market<<

Sirna acquired for $1.1B, SIRT for $720M. I suggest that Big Pharma is no longer only interested in companies which have (at least) established P2b proof-of-principle results in man. They are also interested in landgrabbing IP and expertise in wide-open new areas which *might* result in multi-billion dollar cash flow streams 10-20 years from now.

So what follows the pattern of Sirna and Sirtris?

How about Geron for embryonic stem cells??

micro